menopause%20-and-%20hormone%20therapy
MENOPAUSE & HORMONE THERAPY
Spontaneous/Natural menopause is the final menstrual period confirmed after 12 consecutive months of amenorrhea with no pathological cause.
Induced menopause is the permanent cessation of menstruation after bilateral oophorectomy (ie surgical menopause) or iatrogenic ablation of ovarian function (eg pelvic radiation therapy, chemotherapy).
Perimenopause/Menopause transition/Climacteric is the duration when menstrual cycle & endocrine changes occur a few years before and 12 months after the final menstrual period resulting from natural menopause.
Premature menopause is menopause before 40 years of age whether natural or induced while early menopause is spontaneous or induced menopause that occurs before the average age of natural menopause at 51 years or under 45 years of age.

Spontaneous/Natural Menopause

  • Final menstrual period confirmed after 12 consecutive months of amenorrhea with no pathological cause

Induced Menopause

  • Permanent cessation of menstruation after bilateral oophorectomy (eg surgical menopause) or iatrogenic ablation of ovarian function (eg pelvic radiation therapy, chemotherapy)

Perimenopause/Menopause Transition/Climacteric

  • Duration when menstrual cycle and endocrine changes occur a few years before and 12 months after the final menstrual period resulting from natural menopause
  • Menopausal symptoms that occur in women >45 years of age

Premature Menopause

  • Menopause before or at 40 years of age whether natural or induced
  • Premature ovarian failure is ovarian insufficiency before 40 years of age resulting in permanent or induced amenorrhea

Early Menopause

  • Spontaneous or induced menopause that occurs before the average age of natural menopause at 51 years or under 45 years

Early Postmenopause

  • Occurs within 5 years after the final menstrual period

Signs and Symptoms

Menopausal Symptoms

Related to Hormonal Status

  • Hot flushes
  • Night sweats
  • Dyspareunia
  • Vaginal dryness

Not Related to Hormonal Status 

  • Major depression

Potentially Related to Hormonal Status

  • Lack of energy, fatigue, sleep disturbances, insomnia
  • Depression, anxiety, mood swings, memory loss
  • Joint and muscle pain, backache
  • Urinary incontinence
  • Headaches
  • Weight gain

Risk Factors

Fracture and Osteoporosis

The more risk factors that are present, the greater the risk of fracture

  • May use Fracture Risk Assessment Tool (FRAX), the World Health Organization (WHO) fracture assessment tool

Non-modifiable

  • Previous history of fracture as an adult
  • History of fracture in 1st-degree relative
  •  Advanced age [low body weight and older age (OSTA)]
  • Poor health/frailty
  • Ethnic group (Asians generally have lower risk compared to Caucasians)
  • Early natural or surgical menopause before 45 years or prolonged premenopausal amenorrhea >1 year

Modifiable

  • Recurrent falls
  • Decreased body weight (<125 lb or 57 kg)
  • Impaired vision
  • Medical conditions: Rheumatoid arthritis, estrogen deficiency, vitamin D (Vit D) deficiency due to lack of sunlight exposure or low intake, thyrotoxicosis or prolonged Levothyroxine intake, chronic liver or renal disease, malabsorptive disease
  • Cigarette smoking
  • Excessive alcohol (>3 drinks/day) and caffeine intake
  • Low calcium (Ca) intake
  • Oral glucocorticoid use ≥5 mg/day of prednisone for ≥3 months
  • Sedentary lifestyle (lack of physical activity)
  • Secondary osteoporosis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
01 Oct 2015
BLACKMORES VITAMIN D3 – Vitamin D3 1,000 IU Capsules
15 Dec 2016
New drug applications approved by US FDA as of 1 - 15 December 2016 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Kavitha G. Shekar, 21 Jun 2016

The American Diabetes Association’s (ADA) President Desmond Schatz challenged the scientific community to transform diabetes from an invisible disease to a highly visible crisis. “Diabetes is an epidemic spiralling out of control across this country and around the world, yet it remains largely invisible,” he said, speaking at the 76th Scientific Sessions of ADA in New Orleans, Louisiana, US.

31 Jul 2017
New drug applications approved by US FDA as of 16 - 31 July 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.